|
注册号: Registration number: |
ChiCTR2200061822 |
|
最近更新日期: Date of Last Refreshed on: |
2023-04-05 09:54:09 |
|
注册时间: Date of Registration: |
2022-07-03 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
颅骨修补术后颞肌萎缩的临床研究 |
|
Public title: |
Temporalis muscle classifications and its augmentative resuspension during cranioplasty for minimizing temporal deformity |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
颅骨修补术后颞肌萎缩的临床研究 |
|
Scientific title: |
Temporalis muscle classifications and its augmentative resuspension during cranioplasty for minimizing temporal deformity |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨靖国 |
研究负责人: |
关俊文 |
|
Applicant: |
Jingguo Yang |
Study leader: |
Junwen Guan |
|
申请注册联系人电话: Applicant telephone: |
+86 18981381916 |
研究负责人电话:
Study leader's |
+86 18981381916 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
574627969@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
574627969@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市国学巷37号 |
研究负责人通讯地址: |
四川省成都市国学巷37号 |
|
Applicant address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
Study leader's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021年审(1472)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院临床试验伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee on Clinical Trial, West China Hospital of Sichuan Universit |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
邓邵林 |
||
|
Contact Name of the ethic committee: |
Shaolin Deng |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号老八教412 |
||
|
Contact Address of the ethic committee: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
1.3.5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究疾病: |
颅骨修补后颞肌萎缩 |
||||||||||||||||||||||
|
Target disease: |
temporal hollowing following cranioplasty |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
病例研究 |
||||||||||||||||||||||
|
Study design: |
Case study |
||||||||||||||||||||||
|
研究目的: |
本研究的目的在于对颅骨修补术后萎缩的颞肌进行分类,并且在分类的基础上提出降低颅骨修补术后颞肌进一步萎缩发生的方法。 |
||||||||||||||||||||||
|
Objectives of Study: |
The objective is to present the classifications of temporal muscle and report technical notes and clinical outcome of augmented temporal muscle for minimizing temporal hollowing after cranioplasty. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
排除失访、随访时间小于6个月以及缺乏术前术后外观对比图像的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients loss to follow-up, follow-up time less than 6 months, or lack of preoperative and postoperative appearance contrast images. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-04-01 00:00:00至 To 2022-07-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-06-20 00:00:00 至 To 2022-07-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
联系试验负责人 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact study leader. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集及整理由研究者完成并建立专业数据库,存于本研究专用电脑。临床试验完成后,最终数据将上述数据库录入并提交至ResMan临床试验公共管理平台。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and collation shall be completed by the researcher and a professional database shall be established and stored in the special computer for this study. Upon completion of the clinical trial, the final data will be entered into the above database and submitted to the ResMan clinical trial public management platform. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |